It's not in AZ's interest to keep an expensive factory idled in an environment of unprecedented demand, obviously. They want to sell vaccine to whoever will take it. AZ is "unwilling" to deliver to the EU because it has signed contracts putting other countries first and they are able to consume the entire supply. Once the UK is done, they will suddenly become "willing" (if such a term makes sense when contracts are involved) to deliver to the EU as well.
So to be clear, you are describing factual statements as speculation (which is wrong) and then making spurious claims about AZ/EMA's claimed interests instead of what they're actually doing.
"Rolling review" is the term I've seen typically used for the process that you described, and Wikipedia has references for various rolling reviews by EMA starting with the following: "In October 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) started 'rolling reviews' of the vaccines known as COVID-19 Vaccine AstraZeneca (ChAdOx1-SARS-CoV-2) and Pfizer-BioNTech COVID-19 Vaccine (BNT162b2)." https://en.wikipedia.org/wiki/History_of_COVID-19_vaccine_de...
It is in AZs interest to not start the process which would make the factory available for EU, where AZ is not willing to deliver at this time. (Instead, they ship doses even from the EU factories to UK and elsewhere.)
Given this, you would need something concrete to back your speculation to the contrary.